Abbott Laboratories (ABT- Q3FY20) – Medical Devices and Diagnostics contributed towards revenue growth.

in , on November 12, 2020

Abbott revenues increased by 9.6% to $8.85bn in Q3FY20. The increase was driven by an increase in the Diagnostics segment as a result of demand for Abbott’s portfolio of COVID 19 diagnostics tests on its lab based immunoassay and molecular diagnostics systems and point of care rapid testing platforms. Sales growth in Medical Devices and Diagnostics.

Executive Summary

Financial Statements

– Income Statement and Forecast
– Balance Sheet
– Cash Flow
– Q3FY20 Results Overview
– Q3FY20 Segment Performance
– Q3FY20 Key Developments
– Guidance
– Conclusion
– GAAP to Non GAAP Reconciliation

Historical Performance

– Key Ratios
– Profitability Ratios, Asset Turnover Ratio, Growth Ratio
– Per Share Items and Key Ratios
– Key Cash Flow Items
– P/E Band

Product Performance and Key Developments

– Ownership
– Competition
– Key Developments

Valuation and Consensus Performance

– Relative Valuation
– Analyst Recommendations

Market Price Performance

CrispIdea Coverage

No of Pages : 47

Release Information

  • Released

    November 12, 2020

  • Last Updated

    November 17, 2020